Premium
Oral albendazole for the treatment of cutaneous larva migrans
Author(s) -
JONES S.K.,
REYNOLDS N.J.,
OLIWIECKI SIMONE,
HARMAN R.R.M.
Publication year - 1990
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1990.tb08245.x
Subject(s) - albendazole , cutaneous larva migrans , larva migrans , medicine , dermatology , helminthiasis , pathology , surgery
SUMMARY Cutaneous larva migrans is becoming more common in the U.K. with the popularity of tropical countries as holiday destinations. We describe the increasing use of a new benzimidazole derivative, albendazole, which is very effective in the treatment of cutaneous larva migrans. In contrast to thiabendazole, it is virtually free from side‐effects and should, we feel, become the treatment of choice for this condition.